Glucocerebrosidase and Parkinson disease: Recent advances

Aharon-Peretz, 2004, Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews, N. Engl. J. Med., 351, 1972, 10.1056/NEJMoa033277

Alvarez-Erviti, 2010, Chaperone-mediated autophagy markers in Parkinson disease brains, Arch. Neurol., 67, 1464, 10.1001/archneurol.2010.198

Alvarez-Erviti, 2011, Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission, Neurobiol. Dis., 42, 360, 10.1016/j.nbd.2011.01.029

Angeli, 2013, Genotype and phenotype in Parkinson's disease: lessons in heterogeneity from deep brain stimulation, Mov. Disord., 28, 1370, 10.1002/mds.25535

Bae, 2014, Glucocerebrosidase depletion enhances cell-to-cell transmission of alpha-synuclein, Nat. Commun., 5, 4755, 10.1038/ncomms5755

Beavan, 2013, Glucocerebrosidase mutations and the pathogenesis of Parkinson disease, Ann. Med., 45, 511, 10.3109/07853890.2013.849003

Beavan, 2015, Evolution of prodromal clinical markers of Parkinson disease in a GBA mutation-positive cohort, JAMA Neurol., 72, 201, 10.1001/jamaneurol.2014.2950

Bendikov-Bar, 2013, Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase, Blood Cells Mol. Dis., 50, 141, 10.1016/j.bcmd.2012.10.007

Chung, 2013, Identification and rescue of alpha-synuclein toxicity in Parkinson patient-derived neurons, Science, 342, 983, 10.1126/science.1245296

Clark, 2009, Association of glucocerebrosidase mutations with dementia with Lewy bodies, Arch. Neurol., 66, 578, 10.1001/archneurol.2009.54

Cleeter, 2013, Glucocerebrosidase inhibition causes mitochondrial dysfunction and free radical damage, Neurochem. Int., 62, 1, 10.1016/j.neuint.2012.10.010

Cooper, 2006, Alpha-synuclein blocks ER–Golgi traffic and Rab1 rescues neuron loss in Parkinson's models, Science, 313, 324, 10.1126/science.1129462

Cuervo, 2004, Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy, Science, 305, 1292, 10.1126/science.1101738

Cullen, 2011, Acid beta-glucosidase mutants linked to Gaucher disease, Parkinson disease, and Lewy body dementia alter alpha-synuclein processing, Ann. Neurol., 69, 940, 10.1002/ana.22400

Dermentzaki, 2013, Loss of beta-glucocerebrosidase activity does not affect alpha-synuclein levels or lysosomal function in neuronal cells, PLoS One, 8, e60674, 10.1371/journal.pone.0060674

Duran, 2013, The glucocerobrosidase E326K variant predisposes to Parkinson's disease, but does not cause Gaucher's disease, Mov. Disord., 28, 232, 10.1002/mds.25248

Fishbein, 2014, Augmentation of phenotype in a transgenic Parkinson mouse heterozygous for a Gaucher mutation, Brain, 137, 3235, 10.1093/brain/awu291

Gegg, 2012, Glucocerebrosidase deficiency in substantia nigra of Parkinson disease brains, Ann. Neurol., 72, 455, 10.1002/ana.23614

Goker-Alpan, 2006, Glucocerebrosidase mutations are an important risk factor for Lewy body disorders, Neurology, 67, 908, 10.1212/01.wnl.0000230215.41296.18

Goker-Alpan, 2008, The spectrum of parkinsonian manifestations associated with glucocerebrosidase mutations, Arch. Neurol., 65, 1353, 10.1001/archneur.65.10.1353

Goker-Alpan, 2010, Glucocerebrosidase is present in alpha-synuclein inclusions in Lewy body disorders, Acta Neuropathol., 120, 641, 10.1007/s00401-010-0741-7

Goker-Alpan, 2012, The neurobiology of glucocerebrosidase-associated parkinsonism: a positron emission tomography study of dopamine synthesis and regional cerebral blood flow, Brain, 135, 2440, 10.1093/brain/aws174

Grabowski, 2008, Phenotype, diagnosis, and treatment of Gaucher's disease, Lancet, 372, 1263, 10.1016/S0140-6736(08)61522-6

Horowitz, 1989, The human glucocerebrosidase gene and pseudogene: structure and evolution, Genomics, 4, 87, 10.1016/0888-7543(89)90319-4

Huang, 2011, Contribution of glucocerebrosidase mutation in a large cohort of sporadic Parkinson's disease in Taiwan, Eur. J. Neurol., 18, 1227, 10.1111/j.1468-1331.2011.03362.x

Jamrozik, 2010, Glucocerebrosidase mutations p.L444P and p.N370S are not associated with multisystem atrophy, progressive supranuclear palsy and corticobasal degeneration in Polish patients, J. Neurol., 257, 459, 10.1007/s00415-009-5363-4

Kilpatrick, 2013, Direct mobilisation of lysosomal Ca2+ triggers complex Ca2+ signals, J. Cell Sci., 126, 60, 10.1242/jcs.118836

Kumar, 2013, Glucocerebrosidase mutations in a Serbian Parkinson's disease population, Eur. J. Neurol., 20, 402, 10.1111/j.1468-1331.2012.03817.x

Lesage, 2011, Large-scale screening of the Gaucher's disease-related glucocerebrosidase gene in Europeans with Parkinson's disease, Hum. Mol. Genet., 20, 202, 10.1093/hmg/ddq454

Lieberman, 2009, Effects of pH and iminosugar pharmacological chaperones on lysosomal glycosidase structure and stability, Biochemistry, 48, 4816, 10.1021/bi9002265

Lin, 2014, Genetics and genomics of Parkinson's disease, Genome Med., 6, 48, 10.1186/gm566

Manning-Bog, 2009, Alpha-synuclein-glucocerebrosidase interactions in pharmacological Gaucher models: a biological link between Gaucher disease and parkinsonism, Neurotoxicology, 30, 1127, 10.1016/j.neuro.2009.06.009

Mata, 2008, Glucocerebrosidase gene mutations: a risk factor for Lewy body disorders, Arch. Neurol., 65, 379, 10.1001/archneurol.2007.68

Mazzulli, 2011, Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies, Cell, 146, 37, 10.1016/j.cell.2011.06.001

McNeill, 2012, A clinical and family history study of Parkinson's disease in heterozygous glucocerebrosidase mutation carriers, J. Neurol. Neurosurg. Psychiatry, 83, 853, 10.1136/jnnp-2012-302402

McNeill, 2012, Hyposmia and cognitive impairment in Gaucher disease patients and carriers, Mov. Disord., 27, 526, 10.1002/mds.24945

McNeill, 2013, Retinal thinning in Gaucher disease patients and carriers: results of a pilot study, Mol. Genet. Metab., 109, 221, 10.1016/j.ymgme.2013.04.001

McNeill, 2013, Dopaminergic neuronal imaging in genetic Parkinson's disease: insights into pathogenesis, PLoS One, 8, e69190, 10.1371/journal.pone.0069190

McNeill, 2014, Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells, Brain, 137, 1481, 10.1093/brain/awu020

Mitsui, 2009, Mutations for Gaucher disease confer high susceptibility to Parkinson disease, Arch. Neurol., 66, 571, 10.1001/archneurol.2009.72

Mu, 2008, Chemical and biological approaches synergize to ameliorate protein-folding diseases, Cell, 134, 769, 10.1016/j.cell.2008.06.037

Mullin, 2015, Pathogenic mechanisms of neurodegeneration in Parkinson disease, Neurol. Clin., 33, 1, 10.1016/j.ncl.2014.09.010

Murphy, 2014, Reduced glucocerebrosidase is associated with increased alpha-synuclein in sporadic Parkinson's disease, Brain, 137, 834, 10.1093/brain/awt367

Nalls, 2013, A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies, JAMA Neurol., 70, 727, 10.1001/jamaneurol.2013.1925

Nalls, 2014, Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease, Nat. Genet., 46, 989, 10.1038/ng.3043

Neumann, 2009, Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease, Brain, 132, 1783, 10.1093/brain/awp044

Olanow, 2013, Therapeutic prospects for Parkinson disease, Ann. Neurol., 74, 337, 10.1002/ana.24011

Osellame, 2013, Mitochondria and quality control defects in a mouse model of Gaucher disease—links to Parkinson's disease, Cell Metab., 17, 941, 10.1016/j.cmet.2013.04.014

Panicker, 2012, Induced pluripotent stem cell model recapitulates pathologic hallmarks of Gaucher disease, Proc. Natl. Acad. Sci. U. S. A., 109, 18054, 10.1073/pnas.1207889109

Parkkinen, 2011, Glucocerebrosidase mutations do not cause increased Lewy body pathology in Parkinson's disease, Mol. Genet. Metab., 103, 410, 10.1016/j.ymgme.2011.04.015

Rocha, 2015, Progressive decline of glucocerebrosidase in aging and Parkinson's disease, Ann. Clin. Transl. Neurol., 10.1002/acn3.177

Ron, 2005, ER retention and degradation as the molecular basis underlying Gaucher disease heterogeneity, Hum. Mol. Genet., 14, 2387, 10.1093/hmg/ddi240

Sardi, 2011, CNS expression of glucocerebrosidase corrects alpha-synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy, Proc. Natl. Acad. Sci. U. S. A., 108, 12101, 10.1073/pnas.1108197108

Sardi, 2013, Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies, Proc. Natl. Acad. Sci. U. S. A., 110, 3537, 10.1073/pnas.1220464110

Schapira, 2013, Calcium dysregulation in Parkinson's disease, Brain, 136, 2015, 10.1093/brain/awt180

Schapira, 2013, Glucocerebrosidase in the pathogenesis and treatment of Parkinson disease, Proc. Natl. Acad. Sci. U. S. A., 110, 3214, 10.1073/pnas.1300822110

Schapira, 2011, Etiology and pathogenesis of Parkinson's disease, Mov. Disord., 26, 1049, 10.1002/mds.23732

Schapira, 2014, Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives, Lancet, 384, 545, 10.1016/S0140-6736(14)61010-2

Schondorf, 2014, iPSC-derived neurons from GBA1-associated Parkinson's disease patients show autophagic defects and impaired calcium homeostasis, Nat. Commun., 5, 4028, 10.1038/ncomms5028

Segarane, 2009, Glucocerebrosidase mutations in 108 neuropathologically confirmed cases of multiple system atrophy, Neurology, 72, 1185, 10.1212/01.wnl.0000345356.40399.eb

Sidransky, 2009, Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease, N. Engl. J. Med., 361, 1651, 10.1056/NEJMoa0901281

Srulijes, 2013, No association of GBA mutations and multiple system atrophy, Eur. J. Neurol., 20, e61, 10.1111/ene.12086

Tayebi, 2001, Gaucher disease and parkinsonism: a phenotypic and genotypic characterization, Mol. Genet. Metab., 73, 313, 10.1006/mgme.2001.3201

Thayanidhi, 2010, Alpha-synuclein delays endoplasmic reticulum (ER)-to-Golgi transport in mammalian cells by antagonizing ER/Golgi SNAREs, Mol. Biol. Cell, 21, 1850, 10.1091/mbc.E09-09-0801

Tofaris, 2012, Lysosome-dependent pathways as a unifying theme in Parkinson's disease, Mov. Disord., 27, 1364, 10.1002/mds.25136

Winder-Rhodes, 2013, Glucocerebrosidase mutations influence the natural history of Parkinson's disease in a community-based incident cohort, Brain, 136, 392, 10.1093/brain/aws318

Wong, 2004, Neuropathology provides clues to the pathophysiology of Gaucher disease, Mol. Genet. Metab., 82, 192, 10.1016/j.ymgme.2004.04.011

Yap, 2011, Alpha-synuclein interacts with Glucocerebrosidase providing a molecular link between Parkinson and Gaucher diseases, J. Biol. Chem., 286, 28080, 10.1074/jbc.M111.237859

Yap, 2013, Membrane-bound alpha-synuclein interacts with glucocerebrosidase and inhibits enzyme activity, Mol. Genet. Metab., 108, 56, 10.1016/j.ymgme.2012.11.010

Ziegler, 2007, Glucocerebrosidase mutations in Chinese subjects from Taiwan with sporadic Parkinson disease, Mol. Genet. Metab., 91, 195, 10.1016/j.ymgme.2007.03.004

Zokaei, 2014, Visual short-term memory deficits associated with GBA mutation and Parkinson's disease, Brain, 137, 2303, 10.1093/brain/awu143